


CLINICAL EVIDENCE SUMMARY

# The value of PGx and precision medicine

An overview of the published data  
supporting the utility of pharmacogenetics  
(PGx) in precision medicine



customerservice@genomind.com  
2200 Renaissance Blvd., Suite 100  
King of Prussia, PA 19406


**genomind**<sup>7</sup>  
The Science Behind Better

## AETNA CASE-CONTROL HEALTHCARE UTILIZATION STUDY

Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study

### Study design

Case-control study examining health care utilization and cost among patients with mood disorders following use of Genomind PGx testing (n=817) compared to a matched control group (n=2,745) whose treatment was not guided by Genomind PGx.



### Key findings

Genomind PGx testing was associated with:



40% fewer emergency room visits



58% fewer inpatient hospitalizations



Estimated \$1,948 reduction in health care costs over 6-months


Genomind's Precision Health Platform was associated with decreased healthcare costs per individual over 6 months.

# RANDOMIZED-CONTROLLED TRIAL PGx & DEPRESSION STUDY

Randomized, controlled, participant- and rater-blinded trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder

## Study design

Eight-week multicenter RCT examining the impact of Genomind PGx testing (n=151) versus treatment-as-usual (n=153) among outpatients with major depressive disorder. Both participants and raters were blinded to treatment conditions for the primary outcome (Hamilton Depression Rating Scale; SIGH-D-17).



## Key findings

Post-hoc analyses revealed:



Significantly fewer individuals experienced worsening of depressive symptoms following Genomind PGx testing compared to treatment-as-usual



Individuals receiving treatment that was congruent with PGx recommendations were twice (OR 2.23; 95% CI 1.17-2.83) as likely to remit compared to patients who received incongruent treatment.


In a post-hoc analysis, patients assigned medications congruent with Genomind's PGx test were twice as likely to experience remission

## NATURALISTIC STUDY PGx MOOD & ANXIETY

A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders

### Study design

Naturalistic, open-label study of psychiatric patients who used Genomind PGx testing (n=685) and completed self-report questionnaires assessing depression (Quick Inventory for Depressive Symptoms), anxiety (Zung Self-Rated Anxiety Scale), and quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form).



### Key findings

Results demonstrated a substantial proportion of individuals receiving Genomind PGx testing showed:



Significant decreases in depression, anxiety, and medication side effects



Increased quality of life over 3-months (all  $p < 0.001$ )


87% who used Genomind PGx testing saw clinically measurable mental health improvement

# McLEAN HOSPITAL NATURALISTIC STUDY

## Pharmacogenetic testing in an adult psychiatric inpatient population

### Study design

Open-label pilot study examining the feasibility of Genomind PGx testing in an inpatient unit, examining clinical outcomes including the APA DSM-V Level 1 Cross Cutting Symptom Measure, APA DSM-V Level 2 Cross Cutting Symptom Specific Measure (8 specific symptoms), and the WHODAS 2.0 to assess quality of life, 3 months post-hospitalization in patients with anxiety and depression related diagnoses.



### Key findings

Compared to a control group who did not have PGx testing, participants who received Genomind PGx testing reported:

- Significantly greater reductions in broad psychiatric symptomatology ( $p=.028$ ) and substance use ( $p<.001$ )
- Improved quality of life ( $p=.004$ )

PGx testing linked to significant improvement in psychiatric symptoms and quality of life


King CD, et al. Open-label pilot study of psychiatric pharmacogenetic testing in an adult psychiatric inpatient population. Elsevier. 2020. doi:10.1016/j.pmip.2020.100060

## ROSENBLAT META-ANALYSIS PGx & DEPRESSION STUDY

The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder:  
A meta-analysis

### Study design

Rosenblat and colleagues meta-analytic review examined the effect of PGx testing on remission and response rates specifically in the acute treatment phase of MDD on a total of six studies: four RCTs (also included in the Bousman meta-analysis), as well as two additional open-label, controlled cohort studies. A total of 735 participants were randomized to receive PGx-guided treatment (n=353) versus treatment as usual (n=383).



### Key findings

**40%**  
remission rate

Overall, the PGx-guided treatment participants had a remission rate of 40% as compared to the unguided group, with a pooled remission rate of 25%.

**74%**  
increased odds of remission

In a random-effects meta-analysis examining 735 patients undergoing acute treatment for MDD across the included studies, the pooled risk ratio favored PGx-guided treatment, indicating a 74% increased odds of remission.


PGx testing is associated with increased odds of remission

## BOUSMAN META-ANALYSIS PGx & DEPRESSION STUDY

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials

### Study design

Bousman and colleagues performed a systematic review and meta-analysis examining five randomized controlled trials (RCTs) of the utility of PGx testing in major depressive disorder (MDD) patients (n=1,737). In each individual RCT included in the meta-analysis, patients were randomized to receive PGx-guided treatment (n=887) versus treatment as usual (n=850).



### Key findings

**71%**  
more likely  
to achieve  
remission

Depressed patients receiving PGx-guided treatment were 71% more likely to achieve remission on their medications compared to participants receiving treatment as usual.


PGx category data supports improved remission rates with PGx use

## DAVID META-ANALYSIS OF PGx & HOSPITAL ADMISSIONS STUDY

An analysis of pharmacogenomic-guided pathways and their effect on medication changes and hospital admissions: A systematic review and meta-analysis

### Study design

Systemic review and meta-analysis examining the effect of PGx testing on medication changes and hospitalizations compared to treatment-as-usual (TAU).



### Key findings

**50%**  
less likely to be hospitalized

In the analysis of 5 studies evaluating hospitalizations, participants receiving PGx-guided treatment (n=2,957) were 50% less likely to be hospitalized compared to participants receiving treatment-as-usual (n=6,783).

**91%**  
more likely to have medication changes

In the analysis of 5 studies evaluating medication changes, participants receiving PGx-guided treatment (n=749) were 91% more likely to have medication changes compared to TAU participants (n=825). Medication changes were a result of medication optimization (ex. medication switch, change of dose, or deprescribing).

PGx category data supports improved outcomes with PGx use